Two series of novel phenylaminopyrimidine derivatives were designed and synthesized. All target compounds
were determined against the human acute monocytic leukemia cell line U937 and the human chronic myeloid leukemia
cell line K562 in vitro. Some of the target compounds demonstrated significant inhibitory activity against both cell lines.
Compared with the control drug VX-680, 8a, 8e, 8g, 8h, 8j, and 8k demonstrated more potent antitumor activity. The
structures of all target compounds were identified by 1H-NMR, 13C-NMR, IR, MS, and EA.